Dr. Bair is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1665 Aurora Ct
Aurora, CO 80045Phone+1 720-848-0000Fax+1 720-848-1786
Education & Training
- University of PennsylvaniaMSCE, Clinical Epidemiology, 2018 - 2020
- University of Pennsylvania Health SystemFellowship, Hematology and Medical Oncology, 2017 - 2020
- University of Pennsylvania Health SystemResidency, Internal Medicine, 2014 - 2017
- Case Western Reserve University School of MedicineClass of 2014
Certifications & Licensure
- CO State Medical License 2020 - 2025
- WY State Medical License 2021 - 2025
- PA State Medical License 2014 - 2021
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
Awards, Honors, & Recognition
- The Myron F. Kanter and Lawrence J. Kanter Endowment Award (Cardiology) Case Western Reserve University School of Medicine, 2014
- Alpha Omega Alpha Inductee Alpha Omega Alpha, 2014
Publications & Presentations
PubMed
- 454 citationsNF-κB Directs Dynamic Super Enhancer Formation in Inflammation and AtherogenesisJonathan D. Brown, Charles Y. Lin, Qiong Duan, Gabriel K. Griffin, Alexander J. Federation
Molecular Cell. 2014-10-23 - 21 citationsA validated composite comorbidity index predicts outcomes of CAR T-cell therapy in patients with diffuse large B-cell lymphoma.Geoffrey Shouse, Andy Kaempf, Max J Gordon, Andy Artz, David Yashar
Blood Advances. 2023-07-25 - 25 citationsOutcomes and Toxicities of Programmed Death-1 (PD-1) Inhibitors in Hodgkin Lymphoma Patients in the United States: A Real-World, Multicenter Retrospective Analysis.Steven M. Bair, Lauren E. Strelec, Tatyana Feldman, Gulrayz Ahmed, Philippe Armand
The Oncologist. 2019-07-01
Abstracts/Posters
- Use of Bendamustine for Lymphodepletion before Tisagenlecleucel (anti-CD19 CAR T cells) for Aggressive B-Cell LymphomasSteven M. Bair, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Current Selection Patterns, Toxicities and Outcomes of Pre-Transplant Salvage Treatment Regimens in Patients with Relapsed/Refractory Hodgkin Lymphoma: Results of a Mu...Steven M. Bair, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Lectures
- Checkpoint Blockade Therapy May Sensitize Aggressive and Indolent Non-Hodgkin Lymphoma to Subsequent Therapy2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Checkpoint Blockade Therapy May Sensitize Hodgkin Lymphoma to Subsequent Therapy2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
- The Utility of FDG-PET in the Treatment of Hodgkin LymphomaNovember 6th, 2019
Professional Memberships
- Member
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: